Drug funding ‘not primary focus’ of chemo reviewBy Megan Brodie 3 years ago | In Industry, Regulatory
- 3 years ago
EFC Lead Reviewer Professor Sanchia Aranda
21 May 2021 The appropriate reimbursement, remuneration and payment for chemotherapy medicine providers has been…
This is subscriber-only content. Please login to continue reading.